Five stocks stand out heading into Wednesday, September 23, 2026, each carrying a bullish rating change issued on Tuesday, September 22. The Federal Open Market Committee held the federal funds target range at 3.50% to 3.75% at its July 29 meeting, and the CME Group FedWatch tool still prices roughly an 80% probability that policy rates hold steady through the balance of 2026.
The five ideas below span China internet, U.S. life insurance, medical imaging, pharma packaging, and electronics manufacturing. Editorial notes only, not investment advice.
NetEase (NTES) – BNP Paribas Initiates Bullish on China Internet
Chinese gaming and internet-services operator NetEase drew a fresh Outperform initiation on Tuesday from BNP Paribas. The thesis focuses on domestic mobile-gaming pipeline (upcoming titles across the Marvel Rivals and evergreen franchises) sustaining bookings growth, overseas expansion contributing incremental revenue diversification, and Cloud Music segment continuing to expand paying-user penetration alongside stable operating margins.
Shares traded near $118.36 during Tuesday's session, up about 0.76%, giving NetEase a market capitalization near $76 billion. The 52-week range of $106.06 to $156.44 shows the stock trading near the low end of the year's range. The trailing price-to-earnings multiple sits at 15.76, and the dividend yield sits near 2%.
Consensus reads buy on the broader panel. Three U.S. sell-side firms in the current window cover the name with two bullish and one neutral. The average price target of $160 implies roughly 35% upside from Tuesday's level, and JP Morgan's Daniel Chen sits at the high at $190 following the October 2025 upgrade to Overweight.
Risks: The panel is not uniformly aligned. Barclays' Jiong Shao maintained Equal-Weight at $132 on February 12 (target trimmed from $135), and mobile-gaming regulatory risk in China remains a periodic overhang. Mobile-gaming-pipeline release timing, overseas-expansion traction, and Cloud Music paying-user penetration all remain factors to monitor.
MetLife (MET) – Piper Sandler Turns Bullish on Life Insurance
U.S. life-insurance leader MetLife was upgraded from Neutral to Overweight on Tuesday by Piper Sandler analyst Paul Newsome, who raised his price target to $110 from $99. The thesis focuses on group-benefits segment margin expansion continuing as claims-experience normalizes, retirement-and-income-solutions segment contributing predictable spread-driven earnings, and international segment (Asia, Latin America) providing incremental growth beyond a maturing U.S. base.
Shares traded near $96.05 during Tuesday's session, down about 0.61%, giving MetLife a market capitalization near $62 billion. The 52-week range of $67.33 to $100.93 shows the stock trading near multi-year highs. The trailing price-to-earnings multiple sits at 18.44, and the dividend yield sits near 2%.
Consensus reads strong buy on the broader panel. Twelve sell-side firms cover the name with 11 bullish and one neutral. The average price target of $105 implies roughly 9% upside from Tuesday's level, and Morgan Stanley's Nigel Dally sits at the high at $111 with Overweight on August 24.
Risks: Not all commentary is uniformly aligned. Piper Sandler's own John Barnidge downgraded to Neutral at $84 in September 2025 before Tuesday's reversal from a different analyst, and Mizuho's Yaron Kinar carried Outperform at $93 on April 13 (below current price). Group-benefits margin trajectory, retirement-spread durability, and international-segment growth pace all remain factors to monitor.
GE HealthCare (GEHC) – Needham Initiates Bullish on Medical Imaging
Medical imaging and diagnostics leader GE HealthCare drew a fresh Buy initiation on Tuesday from Needham. The thesis focuses on imaging systems (MRI, CT, molecular imaging) benefiting from replacement-cycle demand across U.S. hospital networks, pharmaceutical-diagnostics segment growth from contrast-media pricing and volume gains, and margin expansion holding as manufacturing efficiencies compound.
Shares traded near $66.11 during Tuesday's session, up about 2.01% on the initiation catalyst, giving GE HealthCare a market capitalization near $30 billion. The 52-week range of $58.75 to $89.77 shows the stock trading in the lower half of the year's range. The trailing price-to-earnings multiple sits at 19.17.
Consensus reads buy on the broader panel. Fourteen sell-side firms cover the name with seven bullish and seven neutral. The average price target of $83 implies roughly 26% upside from Tuesday's level, and the panel high sits at $105.
Risks: The panel is evenly split. UBS's Graham Doyle maintained Neutral at $73 on July 31, and Citigroup's Joanne Wuensch downgraded to Neutral at $83 in October 2025 (target trimmed from $93). Imaging-systems replacement-cycle pace, pharmaceutical-diagnostics pricing trends, and China market recovery timing all remain factors to monitor.
West Pharmaceutical Services (WST) – Morgan Stanley Turns Bullish on Injectable Packaging
Injectable drug-delivery components and packaging leader West Pharmaceutical Services was upgraded from Equal-Weight to Overweight on Tuesday by Morgan Stanley analyst Kallum Titchmarsh, who raised his price target to $400 from $365. The thesis focuses on high-value product mix (Daikyo, NovaPure, Envision) continuing to expand as GLP-1 packaging volumes ramp, biologics customer base extending durable end-market growth, and contract-manufacturing segment providing incremental revenue diversification.
Shares traded near $374.43 during Tuesday's session, up about 3.50% on the upgrade catalyst, giving West Pharmaceutical a market capitalization near $26 billion. The 52-week range of $223.83 to $386 shows the stock trading near multi-year highs. The trailing price-to-earnings multiple sits at 47.86.
Consensus reads strong buy on the broader panel. Seven sell-side firms cover the name with all seven in the bullish camp. The average price target of $400.29 sits roughly in line with Tuesday's level, and Evercore ISI Group's Daniel Markowitz sits at the high at $425.
Risks: Even a fully bullish consensus carries dispersion. Barclays' Luke Sergott held Equal-Weight at $275 in April 2026 before being upgraded to Overweight at $400 in June, and Stephens' Steven Etoch reiterated Overweight at $360 on June 2 (slightly below current price). High-value product-mix trajectory, GLP-1 packaging volume durability, and contract-manufacturing execution all remain factors to monitor.
Plexus (PLXS) – KeyBanc Turns Bullish on Electronics Manufacturing
Electronics-manufacturing-services provider Plexus was upgraded from Sector Weight to Overweight on Tuesday by KeyBanc with a $300 price target. The thesis focuses on healthcare and life-sciences end-market strength continuing to drive bookings growth, industrial end-market volumes recovering as capital-expenditure budgets normalize, and defense end-market program ramps contributing incremental revenue and margin.
Shares traded near $264.06 during Tuesday's session, up about 4.64% on the upgrade catalyst, giving Plexus a market capitalization near $7 billion. The 52-week range of $132.03 to $307.06 shows the stock trading in the upper half of the year's range. The trailing price-to-earnings multiple sits at 39.08.
Consensus reads strong buy on the broader panel. Four sell-side firms cover the name with three bullish and one neutral. The average price target of $252.50 sits roughly in line with Tuesday's level, and Stifel's Ruben Roy sits at the panel high at $330.
Risks: The panel is thin and carries dispersion. The low price target of $150 sits well below Tuesday's level, reflecting caution from Sidoti's Anja Soderstrom (downgraded to Neutral at $150 in October 2025), and end-market mix has historically been cyclical. Healthcare bookings trajectory, industrial-recovery pace, and defense-program-ramp execution all remain factors to monitor.
Found this helpful? Share it with others.